You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Recommendations for the Treatment of Patients with Clinical Stage III Non-Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance and the 2018 Society for Immunotherapy of Cancer Guidance

Version: 4 ID: GL END 7-3 avr 2020
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
A. Robinson, E.T. Vella, P.M. Ellis, R. Goffin, W. Hanna, D. Maziak, A. Swaminath, Y.C. Ung, Lung Cancer Disease Site Group

Guideline Objective

The goal of this guideline was to provide recommendations for the treatment of patients with clinical stage III non-small cell lung cancer.

Patient Population

Patients with Clinical Stage III Non-Small Cell Lung Cancer.

Intended Guideline Users

The intended users are oncologists and thoracic surgeons involved in the treatment of patients with stage III NSCLC.

Research Questions

  1. Should neoadjuvant chemoradiation plus surgery vs. neoadjuvant chemotherapy plus surgery be used in patients with potentially resectable stage III N2 NSCLC?
  2. Should neoadjuvant chemoradiation plus surgery vs. neoadjuvant chemoradiation and no surgery be used in patients with potentially resectable stage III N2 NSCLC?
  3. Should patients with unresectable clinical stage III NSCLC who have not progressed following completion of concurrent chemoradiation be considered for consolidation immunotherapy vs. concurrent chemoradiation alone?
pdf download Full Report (PDF) (1.05 Mo)